Senate Democrats are meeting with President Obama to review health reform progress. read more
Genentech/Roche?s Avastin Makes Progress In Phase III Breast Cancer Trials Studies bode well for new indications, but side effects and high cost present potential barriers to use. read more
The big drug maker will pay as much as $52 million to tap protein expression technology used to make proteins for developing a vaccine candidate. read more
GSK, the third pharma company to publish its payments to health care providers, spent $14.6 million on speaker and consulting fees during the second quarter. read more
FDA complete response letter requests another randomized study of the acute myeloid leukemia drug to show it is safe and increases survival in elderly patients. read more
Cubist pays $92.5 million upfront for a private biotech and its lead programs, hoping to find a complementary product for Cubicin. read more
ODAC will review currently available treatment options and negative treatment effects in subgroups as OSI seeks to expand Tarceva's indication to first-line maintenance and monotherapy in NSCLC. read more
Beneficiaries who specifically ask for the test are eligible for annual testing, even if they report no risk factors, under the assumption they may be unwilling to disclose high-risk behavior. read more
AstraZeneca's JUPITER study could be added to the statin's label if advisory committee is not troubled by signals of gastrointestinal disorders, "confusional state" and diabetes. read more
"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here
